Home > Boards > Other Markets > Foreign Stock Markets > Novo Nordisk A/S (NVO)

DEWHow did this turn out ?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 407
Posts 54,575
Boards Moderated 40
Alias Born 12/16/01
160x600 placeholder
TREND1 Member Level  Thursday, 10/23/14 03:39:33 PM
Re: DewDiligence post# 1
Post # of 49 
DEW
How did this turn out ?
................................

FDA extends NDA review of NVO’s Tresiba (a/k/a degludec) long-acting insulin by three months:

http://in.reuters.com/article/2012/06/08/us-novonordisk-degludec-fda-idINBRE85709520120608

The extension also affects the FDA’s concurrent review of Ryzodeg (a/k/a degludecplus), which is a combination of degludec and NVO’s NovoLog mealtime insulin. The new PDUFA date for both products is 10/29/12.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist